

2018 Cardiac Dysrhythmia Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Cardiac Dysrhythmia Market

https://marketpublishers.com/r/274F13390ABEN.html

Date: June 2018

Pages: 70

Price: US\$ 999.00 (Single User License)

ID: 274F13390ABEN

Abstracts

Cardiac Dysrhythmia refers to abnormal rate of heart beats and effects around 6 million people in the US alone. More than 20% of these patients are hospitalized and 8-9% witness death. The pace of heart beat is irregular, or either more than the normal range (tachycardia) or slower than normal (bradycardia). Primary factors contributing to the Cardiac Dysrhythmia condition include diabetes, smoking, stress while symptoms include palpitations, short of breath etc.

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Cardiac Dysrhythmia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Cardiac Dysrhythmia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Cardiac Dysrhythmia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.



Contents

1 TABLE OF CONTENTS

- 1.1 List of LIST OF FIGURES
- 1.2 List of Tables

2 CARDIAC DYSRHYTHMIA PIPELINE ANALYSIS

- 2.1 Disease and Pipeline Overview
- 2.2 Cardiac Dysrhythmia Pipeline Snapshot
- 2.3 Cardiac Dysrhythmia Pipeline by Phase
- 2.4 Cardiac Dysrhythmia Pipeline by Company
- 2.5 Cardiac Dysrhythmia Pipeline by Mechanism of Action

3 CARDIAC DYSRHYTHMIA- COMPANY WISE PIPELINE ANALYSIS

AETAS Pharma Co.,Ltd

Armgo Pharma, Inc.

Beijing CoSci Med-Tech Co.,Ltd

Gilead Sciences, Inc.

HUYA Bioscience International, LLC

InCarda Therapeutics, Inc.

LATITUDE Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc.

Numerate, Inc.

OMEICOS Therapeutics GmbH

Ono Pharmaceutical Co., Ltd.

Sanofi SA

Servier Laboratories Limited

Sign Path Pharma Inc

4 CARDIAC DYSRHYTHMIA R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details

Therapeutic Candidate Name

Originator

Co-Developer/ License Partner

Orphan Drug Designation



Development Phase Mechanism of Action Current Status Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN CARDIAC DYSRHYTHMIA PIPELINE

6 APPENDIX

- 6.1 About VPA Research
- 6.2 Sources and Research Methodology



List Of Figures

LIST OF FIGURES

- Figure 1: Cardiac Dysrhythmia Pipeline by Phase, H2- 2018
- Figure 2: Cardiac Dysrhythmia Pipeline by Companies, H2- 2018
- Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
- Figure 4: Cardiac Dysrhythmia Pipeline by Mechanism of Action, H2- 2018
- Figure 5: Mechanism Wise Pipeline Drug Phases, H2-2018



List Of Tables

LIST OF TABLES

- Cardiac Dysrhythmia Pipeline by Phase, H2- 2018
- Cardiac Dysrhythmia Pipeline by Companies, H2- 2018
- Cardiac Dysrhythmia Pipeline by Mechanism of Action, H2-2018
- Table 1: AETAS Pharma Co., Ltd Cardiac Dysrhythmia Pipeline Drugs, H2-2018
- Table 2: Armgo Pharma, Inc. Cardiac Dysrhythmia Pipeline Drugs, H2-2018
- Table 3: Beijing CoSci Med-Tech Co.,Ltd Cardiac Dysrhythmia Pipeline Drugs, H2-2018
- Table 4: Gilead Sciences, Inc. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
- Table 5: HUYA Bioscience International, LLC Cardiac Dysrhythmia Pipeline Drugs, H2-2018
- Table 6: InCarda Therapeutics, Inc. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
- Table 7: LATITUDE Pharmaceuticals Inc. Cardiac Dysrhythmia Pipeline Drugs, H2-2018
- Table 8: Milestone Pharmaceuticals Inc. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
- Table 9: Numerate, Inc. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
- Table 10: OMEICOS Therapeutics GmbH Cardiac Dysrhythmia Pipeline Drugs, H2-2018
- Table 11: Ono Pharmaceutical Co., Ltd. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
- Table 12: Sanofi SA Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
- Table 13: Servier Laboratories Limited Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
- Table 14: Sign Path Pharma Inc Cardiac Dysrhythmia Pipeline Drugs, H2- 2018



I would like to order

Product name: 2018 Cardiac Dysrhythmia Drug Development Pipeline Analysis Report- Companies,

Drugs, Clinical Trials, Latest Developments in Cardiac Dysrhythmia Market

Product link: https://marketpublishers.com/r/274F13390ABEN.html

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/274F13390ABEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to $+44\ 20\ 7900\ 3970$

